2025/06/17 更新

写真a

コウノ ミチヒサ
河野 通久
KONO Michihisa
所属
病院 診療科 耳鼻咽喉科・頭頸部外科
外部リンク

学位

  • 医学博士 ( 2024年   旭川医科大学 )

研究キーワード

  • 免疫

  • 頭頸部腫瘍

研究分野

  • ライフサイエンス / 免疫学

  • ライフサイエンス / 耳鼻咽喉科学

  • ライフサイエンス / 腫瘍生物学

  • ライフサイエンス / 腫瘍診断、治療学

経歴

  • 旭川医科大学   耳鼻咽喉科・頭頸部外科

    2024年

      詳細を見る

  • ハーバード大学 ダナ・ファーバー癌研究所   Medical Oncology   Research Fellow

    2022年

      詳細を見る

  • 旭川医科大学   耳鼻咽喉科・頭頸部外科

    2019年

      詳細を見る

  • 北見赤十字病院   頭頸部・耳鼻咽喉科

    2018年

      詳細を見る

  • 北斗病院   耳鼻咽喉科・頭頸部外科

    2017年

      詳細を見る

  • 旭川医科大学   耳鼻咽喉科・頭頸部外科

    2016年

      詳細を見る

  • 旭川厚生病院 初期臨床研修医

    2014年4月

      詳細を見る

▼全件表示

所属学協会

▼全件表示

論文

  • Differences in PD-L1, PD-L2, and EGFR Expression Between Naive and Recurrent Tumors in Patients With Head and Neck Squamous Cell Carcinoma: A Retrospective Study. 国際誌

    Ryosuke Sato, Takahiro Inoue, Risa Wakisaka, Hiroki Komatsuda, Michihisa Kono, Hidekiyo Yamaki, Kenzo Ohara, Takumi Kumai, Akemi Kosaka, Takayuki Ohkuri, Toshihiro Nagato, Kan Kishibe, Hiroya Kobayashi, Miki Takahara

    Head & neck   2025年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: The efficacy of anti-PD-1 and EGFR therapies for head and neck squamous cell carcinoma (HNSCC) can be predicted using various markers; however, the stability of these markers remains unclear. METHODS: In this retrospective study, laboratory findings and tissue expression of PD-L1, PD-L2, and EGFR were analyzed in 79 paired naive and recurrent HNSCC tumors. Laboratory findings were also analyzed in nonrecurrent patients using a propensity score-matched analysis. PD-L1 and PD-L2 expression levels were assessed using tumor proportion score (TPS) and combined positive score (CPS), whereas EGFR was evaluated using the H-score. RESULTS: White blood cell, neutrophil, lymphocyte, and monocyte counts and lymphocyte-monocyte ratios were significantly lower in the patients after the first-line treatment regardless of recurrence. PD-L1, PD-L2, and EGFR expression changed in 30%-40% of tumor pairs. Immune but not tumoral PD-L1 positivity rates were significantly higher in the patients with early recurrence. CONCLUSIONS: The expression of immune checkpoints including PD-L1 in naive tumors does not reflect those in recurrent tumors. Increasing PD-L1 expression in immune cells may cause early recurrence of HNSCC.

    DOI: 10.1002/hed.28151

    PubMed

    researchmap

  • Prognostic Value of the 18F-FDG PET/CT and Haematological Parameters in Head and Neck Cancer. 査読 国際誌

    Risa Wakisaka, Takumi Kumai, Hiroki Komatsuda, Hidekiyo Yamaki, Michihisa Kono, Ryosuke Sato, Kenzo Ohara, Kan Kishibe, Tatsuya Hayashi, Atsutaka Okizaki, Miki Takahara

    Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery   49 ( 6 )   733 - 741   2024年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    INTRODUCTION: Fluorine 18-fluoro-glucose positron emission tomography/computed tomography (18F-FDG PET/CT) is commonly used for the staging of head and neck cancer. This study aimed to evaluate the correlation between 18F-FDG PET/CT, haematological parameters and prognosis in patients with advanced head and neck cancer. METHODS: This was a single-institutional retrospective study of 83 patients with advanced head and neck squamous cell carcinoma (HNSCC) who underwent 18F-FDG PET/CT imaging before initial treatment between 2014 and 2018. 18F-FDG PET/CT after treatment was performed in 57 patients. The prognostic parameters of the pre- and post-treatment maximum standardised uptake value (SUVmax), metabolic tumour volume (MTV), total lesion glycolysis (TLG) of primary tumours and haematological parameters were analysed to evaluate the association between overall survival (OS) and progression-free survival (PFS). RESULTS: Pre-MTV, pre-TLG and post-SUVmax were significantly associated with poor OS and PFS (p < 0.05). Haematological parameters, including pretreatment neutrophil/lymphocyte ratio and C-reactive protein/albumin ratio, were associated with 18F-FDG PET/CT parameters. In multivariate analysis, post-SUVmax was an independent prognostic factor for OS and PFS. CONCLUSION: A correlation between PET/CT metabolic and haematological parameters was observed. The volume and intensity of 18F-FDG uptake region, in addition to haematological parameters, are feasible markers for predicting the progression of HNSCC in daily practice. Further, post-SUVmax could be an independent parameter for predicting poor survival.

    DOI: 10.1111/coa.14195

    PubMed

    researchmap

  • 頭頸部癌の増殖および腫瘍免疫におけるフェロトーシスの影響について(Effect of ferroptosis on proliferation and tumor immunity in head and neck cancer)

    脇坂 理紗, 熊井 琢美, 河野 通久, 大原 賢三, 長門 利純, 大栗 敬幸, 小坂 朱, 小林 博也, 高原 幹

    日本癌学会総会記事   83回   P - 2228   2024年9月

     詳細を見る

    記述言語:英語   出版者・発行元:(一社)日本癌学会  

    researchmap

  • 頭頸部癌においてがんワクチンはT細胞欠失誘導性免疫抵抗性を克服する(Cancer vaccine overcomes T cell deletion-induced immune resistance in head and neck cancer)

    河野 通久, 熊井 琢美, 小松田 浩樹, 脇坂 理紗, 山木 英聖, 大原 賢三, 岸部 幹, ラビンドラ・ウッパルリ, 高原 幹

    日本癌学会総会記事   83回   P - 2227   2024年9月

     詳細を見る

    記述言語:英語   出版者・発行元:(一社)日本癌学会  

    researchmap

  • 上咽頭癌における可溶性CD27の発現と腫瘍内CD70/CD27インタラクションに対するバイオマーカーとしての可能性(Expression of soluble CD27 in nasopharyngeal carcinoma: potential as a biomarker for intra-tumoral CD70/CD27 interaction)

    長門 利純, 小松田 浩樹, 林 隆介, 氏家 菜々美, 小坂 朱, 大栗 敬幸, 井上 貴博, 佐藤 遼介, 脇坂 理紗, 河野 通久, 山木 英聖, 大原 賢三, 熊井 琢美, 岸部 幹, 高原 幹, 小林 博也

    日本癌学会総会記事   83回   P - 2225   2024年9月

     詳細を見る

    記述言語:英語   出版者・発行元:(一社)日本癌学会  

    researchmap

  • 上咽頭癌における可溶性CD27の発現と腫瘍内CD70/CD27インタラクションに対するバイオマーカーとしての可能性(Expression of soluble CD27 in nasopharyngeal carcinoma: potential as a biomarker for intra-tumoral CD70/CD27 interaction)

    長門 利純, 小松田 浩樹, 林 隆介, 氏家 菜々美, 小坂 朱, 大栗 敬幸, 井上 貴博, 佐藤 遼介, 脇坂 理紗, 河野 通久, 山木 英聖, 大原 賢三, 熊井 琢美, 岸部 幹, 高原 幹, 小林 博也

    日本癌学会総会記事   83回   P - 2225   2024年9月

     詳細を見る

    記述言語:英語   出版者・発行元:(一社)日本癌学会  

    researchmap

  • Combined approach for predicting the efficacy of nivolumab in head and neck carcinoma by tissue and soluble expressions of PD-L1 and PD-L2. 査読 国際誌

    Ryosuke Sato, Hiroki Komatsuda, Takahiro Inoue, Risa Wakisaka, Michihisa Kono, Hidekiyo Yamaki, Kenzo Ohara, Takumi Kumai, Kan Kishibe, Tatsuya Hayashi, Miki Takahara

    Head & neck   46 ( 9 )   2233 - 2243   2024年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Predictive biomarkers for nivolumab in recurrent or metastatic head and neck squamous cell carcinoma (RMHNSCC) have not yet been established. METHODS: The tumor proportion score (TPS), combined positive score (CPS), and soluble forms of programmed cell death ligand-1 (PD-L1) and programmed cell death ligand-2 (PD-L2) were retrospectively analyzed in patients with RMHNSCC treated with nivolumab. RESULTS: The positivity rates for TPS (PD-L1), CPS (PD-L1), TPS (PD-L2), and CPS (PD-L2) were 73.8%, 78.2%, 56.4%, and 78.2%, respectively. Patients with high TPS (PD-L1), CPS (PD-L1), or CPS (PD-L1 and PD-L2) showed significantly prolonged progression-free survival. Favorable overall survival was associated with high CPS (PD-L1 and PD-L2) and low soluble PD-L1 and PD-L2 levels. The expressions of tissue and soluble PD-L1/2 were not correlated. CONCLUSIONS: Our study revealed that compared to PD-L1 expression alone, dual expression of PD-L1 and PD-L2 in tissue or soluble form could be feasible biomarkers in patients with RMHNSCC who received nivolumab.

    DOI: 10.1002/hed.27787

    PubMed

    researchmap

  • Hypoxia-Targeted Immunotherapy with PD-1 Blockade in Head and Neck Cancer. 査読 国際誌

    Risa Wakisaka, Hidekiyo Yamaki, Michihisa Kono, Takahiro Inoue, Ryosuke Sato, Hiroki Komatsuda, Kenzo Ohara, Akemi Kosaka, Takayuki Ohkuri, Toshihiro Nagato, Kan Kishibe, Koh Nakayama, Hiroya Kobayashi, Takumi Kumai, Miki Takahara

    Cancers   16 ( 17 )   2024年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Intratumoral hypoxia is associated with tumor progression, aggressiveness, and therapeutic resistance in several cancers. Hypoxia causes cancer cells to experience replication stress, thereby activating DNA damage and repair pathways. MutT homologue-1 (MTH1, also known as NUDT1), a member of the Nudix family, maintains the genomic integrity and viability of tumor cells in the hypoxic tumor microenvironment. Although hypoxia is associated with poor prognosis and can cause therapeutic resistance by regulating the microenvironment, it has not been considered a treatable target in cancer. This study aimed to investigate whether hypoxia-induced MTH1 is a useful target for immunotherapy and whether hypoxic conditions influence the antitumor activity of immune cells. Our results showed that MTH1 expression was elevated under hypoxic conditions in head and neck cancer cell lines. Furthermore, we identified a novel MTH1-targeting epitope peptide that can activate peptide-specific CD4+ helper T cells with cytotoxic activity. The proliferation and cytotoxic activity of T cells were maintained under hypoxic conditions, and PD-1 blockade further augmented the cytotoxicity. These results indicate that MTH1-targeted immunotherapy combined with checkpoint blockade can be an effective strategy for the treatment of hypoxic tumors.

    DOI: 10.3390/cancers16173013

    PubMed

    researchmap

  • Immunotherapy targeting tumor-associated antigen in a mouse model of head and neck cancer. 査読 国際誌

    Michihisa Kono, Risa Wakisaka, Hiroki Komatsuda, Ryusuke Hayashi, Takumi Kumai, Hidekiyo Yamaki, Ryosuke Sato, Toshihiro Nagato, Takayuki Ohkuri, Akemi Kosaka, Kenzo Ohara, Kan Kishibe, Hiroya Kobayashi, Tatsuya Hayashi, Miki Takahara

    Head & neck   46 ( 8 )   2056 - 2067   2024年8月

     詳細を見る

    担当区分:筆頭著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: The identification of epitope peptides from tumor-associated antigens (TAAs) is informative for developing tumor-specific immunotherapy. However, only a few epitopes have been detected in mouse TAAs of head and neck cancer (HNSCC). METHODS: Novel mouse c-Met-derived T-cell epitopes were predicted by computer-based algorithms. Mouse HNSCC cell line-bearing mice were treated with a c-Met peptide vaccine. The effects of CD8 and/or CD4 T-cell depletion, and vaccine combination with immune checkpoint inhibitors (ICIs) were evaluated. Tumor re-inoculation was performed to assess T-cell memory. RESULTS: We identified c-Met-derived short and long epitopes that elicited c-Met-reactive antitumor CD8 and/or CD4 T-cell responses. Vaccination using these peptides showed remarkable antitumor responses via T cells in which ICIs were not required. The c-Met peptide-vaccinated mice rejected the re-inoculated tumors. CONCLUSIONS: We demonstrated that novel c-Met peptide vaccines can induce antitumor T-cell response, and could be a potent immunotherapy in a syngeneic mouse HNSCC model.

    DOI: 10.1002/hed.27703

    PubMed

    researchmap

  • Cancer vaccine attenuates carcinogen induced head and neck cancer with impaired early T cell response

    Michihisa Kono, Masahiro Rokugo, John D. Quadarella, Shin Saito, Hiroki Komatsuda, Cong Fu, Sook-Bin Woo, Ann Marie Egloff, Ravindra Uppaluri

    2024年6月

     詳細を見る

    担当区分:筆頭著者   出版者・発行元:Cold Spring Harbor Laboratory  

    ABSTRACT

    Effective T cell immunotherapy requires understanding antigen-specific T cell development during tumorigenesis and immune surveillance. Here, we aimed to examine the dynamics of antigen-specific T cells from tumor initiation through progression in a tobacco carcinogen mimetic, 4-nitroquinoline-1-oxide (4NQO)-induced head and neck carcinogenesis model utilizing genetically engineered K5<sup>CreERT/+</sup>/ROSA<sup>OVA-GFP</sup>/p53<sup>fl/fl</sup>(KOG) mice. Our findings showed that early ovalbumin (OVA) expression via direct lingual tamoxifen (T) did not impact cancer development and survival, by comparing mice with tongue epithelium expressing OVA (KOG/T/OVA<sup>+</sup>) to those without OVA (KOG/T/OVA<sup>-</sup>) controlled by doxycycline. This equivalent tumor growth cannot be attributed to the loss of OVA expression. Intriguingly, although OVA-specific T cells were initially generated in tumor-draining lymph nodes (TDLN), they became undetectable 3 weeks after tamoxifen injection. Moreover, therapeutic anti-PD-1 was unable to restore OVA-specific T cells in TDLN and did not yield anti-tumor activity. Remarkably, OVA synthetic long peptide (SLP) vaccine induced OVA-specific T cells in KOG/T/OVA+ mice, and the combination of SLP vaccine and anti-PD-1 significantly reduced tongue tumor burden and prolonged survival. This study highlights the role of impaired endogenous antigen-specific T cell responses in immune resistance in head and neck cancer and the potential of cancer vaccines to improve outcomes.

    DOI: 10.1101/2024.06.26.600828

    researchmap

  • Targeting Dendritic Cell Dysfunction to Circumvent Anti-PD1 Resistance in Head and Neck Cancer. 査読 国際誌

    Shin Saito, Michihisa Kono, Hoang C B Nguyen, Ann Marie Egloff, Cameron Messier, Patrick Lizotte, Cloud Paweletz, Douglas Adkins, Ravindra Uppaluri

    Clinical cancer research : an official journal of the American Association for Cancer Research   30 ( 9 )   1934 - 1944   2024年5月

     詳細を見る

    担当区分:筆頭著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    PURPOSE: Neoadjuvant anti-PD1 (aPD1) therapies are being explored in surgically resectable head and neck squamous cell carcinoma (HNSCC). Encouraging responses have been observed, but further insights into the mechanisms underlying resistance and approaches to improve responses are needed. EXPERIMENTAL DESIGN: We integrated data from syngeneic mouse oral carcinoma (MOC) models and neoadjuvant pembrolizumab HNSCC patient tumor RNA-sequencing data to explore the mechanism of aPD1 resistance. Tumors and tumor-draining lymph nodes (DLN) from MOC models were analyzed for antigen-specific priming. CCL5 expression was enforced in an aPD1-resistant model. RESULTS: An aPD1-resistant mouse model showed poor priming in the tumor DLN due to type 1 conventional dendritic cell (cDC1) dysfunction, which correlated with exhausted and poorly responsive antigen-specific T cells. Tumor microenvironment analysis also showed decreased cDC1 in aPD1-resistant tumors compared with sensitive tumors. Following neoadjuvant aPD1 therapy, pathologic responses in patients also positively correlated with baseline transcriptomic cDC1 signatures. In an aPD1-resistant model, intratumoral cDC1 vaccine was sufficient to restore aPD1 response by enhancing T-cell infiltration and increasing antigen-specific responses with improved tumor control. Mechanistically, CCL5 expression significantly correlated with neoadjuvant aPD1 response and enforced expression of CCL5 in an aPD1-resistant model, enhanced cDC1 tumor infiltration, restored antigen-specific responses, and recovered sensitivity to aPD1 treatment. CONCLUSIONS: These data highlight the contribution of tumor-infiltrating cDC1 in HNSCC aPD1 response and approaches to enhance cDC1 infiltration and function that may circumvent aPD1 resistance in patients with HNSCC.

    DOI: 10.1158/1078-0432.CCR-23-3477

    PubMed

    researchmap

  • Enhanced oral versus flank lymph node T cell response parallels anti-PD1 efficacy in head and neck cancer. 査読 国際誌

    Michihisa Kono, Shin Saito, Masahiro Rokugo, Ann Marie Egloff, Ravindra Uppaluri

    Oral oncology   152   106795 - 106795   2024年5月

     詳細を見る

    担当区分:筆頭著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    OBJECTIVES: Understanding head and neck tissue specific immune responses is important for elucidating immunotherapy resistance mechanisms to head and neck squamous cell carcinoma (HNSCC). In this study, we aimed to investigate HNSCC-specific immune response differences between oral and subcutaneous flank tumor transplantation in preclinical models. MATERIALS AND METHODS: The MOC1 syngeneic mouse oral carcinoma cell line or versions expressing either the H2Kb-restricted SIINFEKL peptide from ovalbumin (MOC1OVA) or ZsGreen (MOC1ZsGreen) were inoculated into mouse oral mucosa (buccal space) or subcutaneous flank and compared for immune cell kinetics in tumors and tumor-draining lymph nodes (TDLNs) and for anti-PD1 response. RESULTS: Compared to subcutaneous flank tumors, orthotopic oral MOC1OVA induced a higher number of OVA-specific T cells, PD1 + or CD69 + activated OVA-specific T cells in both primary tumors and TDLNs. Tumors were also larger in the flank site and CD8 depletion eliminated the difference in tumor weight between the two sites. Oral versus flank SIINFEKL peptide vaccination showed enhanced TDLN lymphocyte response in the former site. Notably, cDC1 from oral TDLN showed enhanced antigen uptake and co-stimulatory marker expression, resulting in elicitation of an increased antigen specific T cell response and increased activated T cells. Parental MOC1 in the oral site showed increased endogenous antigen-reactive T cells in TDLNs and anti-PD1 blockade rejected oral MOC1 tumors but not subcutaneous flank MOC1. CONCLUSION: Collectively, we find distinct immune responses between orthotopic oral and heterotopic subcutaneous models, including priming by cDC1 in TDLN, revealing important implications for head and neck cancer preclinical studies.

    DOI: 10.1016/j.oraloncology.2024.106795

    PubMed

    researchmap

  • Soluble CD27 as a predictive biomarker for intra-tumoral CD70/CD27 interaction in nasopharyngeal carcinoma. 査読 国際誌

    Toshihiro Nagato, Hiroki Komatsuda, Ryusuke Hayashi, Miki Takahara, Nanami Ujiie, Akemi Kosaka, Takayuki Ohkuri, Kensuke Oikawa, Ryosuke Sato, Risa Wakisaka, Michihisa Kono, Hidekiyo Yamaki, Kenzo Ohara, Takumi Kumai, Kan Kishibe, Akihiro Katada, Tatsuya Hayashi, Hiroya Kobayashi

    Cancer science   115 ( 4 )   1073 - 1084   2024年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    In CD70-expressing tumors, the interaction of CD70 on tumor cells with its lymphocyte receptor, CD27, is thought to play a role in immunosuppression in the tumor microenvironment and elevated serum levels of soluble CD27 (sCD27). Previous studies showed that CD70 is expressed in nasopharyngeal carcinoma (NPC), an Epstein-Barr virus (EBV)-related malignancy. However, the association between intratumoral CD70/CD27 expression and serum levels of sCD27 in NPC remains unclear. In the present study, we show that CD70 is primarily expressed by tumor cells in NPC and that CD27-positive lymphocytes infiltrate around tumor cells. NPC patients with CD27-positive lymphocytes had significantly better prognosis than patients lacking these cells. In addition, high CD70 expression by tumor cells tended to be correlated with shorter survival in NPC patients with CD27-positive lymphocytes. Serum sCD27 levels were significantly increased in patients with NPC and provided good diagnostic accuracy for discriminating patients from healthy individuals. The concentration of serum sCD27 in patients with CD70-positive NPC with CD27-positive lymphocytes was significantly higher than in patients with tumors negative for CD70 and/or CD27, indicating that the intratumoral CD70/CD27 interaction boosts the release of sCD27. Furthermore, positive expression of CD70 by NPC cells was significantly correlated with EBV infection. Our results suggest that CD70/CD27-targeted immunotherapies may be promising treatment options and that sCD27 may become an essential tool for evaluating the applicability of these therapies by predicting the intratumoral CD70/CD27 interaction in NPC.

    DOI: 10.1111/cas.16079

    PubMed

    researchmap

  • Efficacy of Cetuximab Combined with Paclitaxel in Patients with Recurrent Salivary Gland Carcinoma: A Retrospective Observational Study. 査読 国際誌

    Ryosuke Sato, Ryota Yuasa, Takumi Kumai, Risa Wakisaka, Hiroki Komatsuda, Michihisa Kono, Hidekiyo Yamaki, Yoshiya Ishida, Tetsuji Wada, Miki Takahara, Akihiro Katada

    ORL; journal for oto-rhino-laryngology and its related specialties   86 ( 1 )   41 - 49   2024年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    INTRODUCTION: Due to the rarity and various histological types, a standard chemotherapy regimen for recurrent or metastatic salivary gland carcinoma (SGC) has not been established. Molecular-targeted therapy is a novel cancer therapy based on the expression of target molecules. However, few molecular-targeted therapy types have shown satisfactory efficacy for patients with SGC. Our study described promising results of epidermal growth factor receptor (EGFR)-targeting therapy with paclitaxel in patients with SGC. METHODS: The medical records of patients with recurrent SGC treated with weekly cetuximab combined with paclitaxel (Cmab-PTX) between December 2017 and December 2022 at our institutions were retrospectively analyzed. RESULTS: Seven patients with SGC received Cmab-PTX therapy. The median age was 76 years. All patients were high-grade histological types, and EGFR expression was positive in all examined patients. Cmab-PTX was administered for a median period of 20 months (range of 2-36 months). The overall responses were three with complete response, two with partial response, one with stable disease (&gt;24 weeks), and one with progressive disease. The objective response and disease control rates were 71.4% and 85.7%, respectively. Progression-free survival ranged between 2 and 36 months (median 12 months), whereas overall survival ranged between 4 and 111 months (median 36 months). One patient experienced a grade 4 adverse event (neutropenia), which was conservatively manageable. CONCLUSION: Although the treatment sensitivity of SGC with high-grade histological types is usually poor, Cmab-PTX could be a promising treatment regimen for recurrent SGC. Due to the rarity and various histological types, a standard chemotherapy regimen for recurrent or metastatic salivary gland carcinoma (SGC) has not been established. Molecular-targeted therapy is a novel cancer therapy based on the expression of target molecules. However, few molecular-targeted therapy types have shown satisfactory efficacy in patients with SGC. Our study described promising results of cetuximab (Cmab), epidermal growth factor receptor (EGFR)-targeting therapy with paclitaxel (PTX) in patients with SGC. Seven patients with SGC received Cmab-PTX therapy. The median age was 76 years. All patients were high-grade histological types, and EGFR expression was positive in all examined patients. Cmab-PTX was administered for a median period of 20 months. The overall responses were three with complete response, two with partial response, one with stable disease (&gt;24 weeks), and one with progressive disease. The objective response rate was 71.4%. Progression-free survival ranged between 2 and 36 months (median 12 months), whereas overall survival ranged between 4 and 111 months (median 36 months). One patient experienced a grade 4 adverse event (neutropenia), which was conservatively manageable. Our study revealed a preferable objective response rate of Cmab-PTX for patients with high-grade SGC. Although the treatment sensitivity of SGC with high-grade histological types is usually poor, Cmab-PTX could be a promising treatment regimen for recurrent SGC.

    DOI: 10.1159/000534516

    PubMed

    researchmap

  • Harnessing Immunity to Treat Advanced Thyroid Cancer. 査読 国際誌

    Hiroki Komatsuda, Michihisa Kono, Risa Wakisaka, Ryosuke Sato, Takahiro Inoue, Takumi Kumai, Miki Takahara

    Vaccines   12 ( 1 )   2023年12月

     詳細を見る

    担当区分:筆頭著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The incidence of thyroid cancer (TC) has increased over the past 30 years. Although differentiated thyroid cancer (DTC) has a good prognosis in most patients undergoing total thyroidectomy followed by radioiodine therapy (RAI), 5-10% of patients develop metastasis. Anaplastic thyroid cancer (ATC) has a low survival rate and few effective treatments have been available to date. Recently, tyrosine kinase inhibitors (TKIs) have been successfully applied to RAI-resistant or non-responsive TC to suppress the disease. However, TC eventually develops resistance to TKIs. Immunotherapy is a promising treatment for TC, the majority of which is considered an immune-hot malignancy. Immune suppression by TC cells and immune-suppressing cells, including tumor-associated macrophages, myeloid-derived suppressor cells, and regulatory T cells, is complex and dynamic. Negative immune checkpoints, cytokines, vascular endothelial growth factors (VEGF), and indoleamine 2,3-dioxygenase 1 (IDO1) suppress antitumor T cells. Basic and translational advances in immune checkpoint inhibitors (ICIs), molecule-targeted therapy, tumor-specific immunotherapy, and their combinations have enabled us to overcome immune suppression and activate antitumor immune cells. This review summarizes current findings regarding the immune microenvironment, immunosuppression, immunological targets, and immunotherapy for TC and highlights the potential efficacy of immunotherapy.

    DOI: 10.3390/vaccines12010045

    PubMed

    researchmap

  • Central-part laryngectomy after laryngotracheal separation to manage pharyngocutaneous fistula: A case report and retrospective analysis of 12 cases. 査読 国際誌

    Kenzo Ohara, Akihiro Katada, Takumi Kumai, Hisataka Ominato, Yui Hirata-Nozaki, Tomoaki Sabusawa, Hidekiyo Yamaki, Michihisa Kono, Hiroki Komatsuda, Risa Wakisaka, Miki Takahara, Tatsuya Hayashi, Yasuaki Harabuchi

    Auris, nasus, larynx   50 ( 4 )   628 - 631   2023年8月

     詳細を見る

    記述言語:英語  

    A 15-year-old girl presented with a 3-year-history of continuous outflow of saliva from a pharyngocutaneous fistula, located at 5 mm superior to her tracheal stoma. She was diagnosed with Miller-Dieker syndrome at birth. At 2 years of age, pediatric surgeons at our institution carried out laryngotracheal separation to prevent aspiration pneumonia. At the age of 12 years, she developed continuous saliva discharge from the fistula. We performed central-part laryngectomy and resection of the pharyngocutaneous fistula, which relieved her from the continuous saliva discharge. Central-part laryngectomy is less invasive and easier to perform than total laryngectomy. We hereby present a case and retrospective analysis of 12 patients, who underwent central-part laryngectomy.

    DOI: 10.1016/j.anl.2022.04.011

    PubMed

    researchmap

  • Brachyury-targeted immunotherapy combined with gemcitabine against head and neck cancer. 査読 国際誌

    Hidekiyo Yamaki, Michihisa Kono, Risa Wakisaka, Hiroki Komatsuda, Takumi Kumai, Ryusuke Hayashi, Ryosuke Sato, Toshihiro Nagato, Takayuki Ohkuri, Akemi Kosaka, Kenzo Ohara, Kan Kishibe, Miki Takahara, Tatsuya Hayashi, Hiroya Kobayashi, Akihiro Katada

    Cancer immunology, immunotherapy : CII   72 ( 8 )   2799 - 2812   2023年8月

     詳細を見る

    担当区分:筆頭著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Brachyury is a transcription factor belonging to the T-box gene family and is involved in the posterior formation of the mesoderm and differentiation of chordates. As the overexpression of Brachyury is a poor prognostic factor in a variety of cancers, the establishment of Brachyury-targeted therapy would be beneficial for the treatment of aggressive tumors. Because transcription factors are difficult to treat with a therapeutic antibody, peptide vaccines are a feasible approach for targeting Brachyury. In this study, we identified Brachyury-derived epitopes that elicit antigen-specific and tumor-reactive CD4+ T cells that directly kill tumors. T cells recognizing Brachyury epitopes were present in patients with head and neck squamous cell carcinoma. Next, we focused on gemcitabine (GEM) as an immunoadjuvant to augment the efficacy of antitumor responses by T cells. Interestingly, GEM upregulated HLA class I and HLA-DR expression in tumor, followed by the upregulation of anti-tumor T cell responses. As tumoral PD-L1 expression was also augmented by GEM, PD-1/PD-L1 blockade and GEM synergistically enhanced the tumor-reactivity of Brachyury-reactive T cells. The synergy between the PD-1/PD-L1 blockade and GEM was also confirmed in a mouse model of head and neck squamous cell carcinoma. These results suggest that the combined treatment of Brachyury peptide with GEM and immune checkpoint blockade could be a promising immunotherapy against head and neck cancer.

    DOI: 10.1007/s00262-023-03460-0

    PubMed

    researchmap

  • Expression of soluble CD27 in extranodal natural killer/T-cell lymphoma, nasal type: potential as a biomarker for diagnosis and CD27/CD70-targeted therapy. 査読 国際誌

    Toshihiro Nagato, Hiroki Komatsuda, Ryusuke Hayashi, Miki Takahara, Kan Kishibe, Shunsuke Yasuda, Yuki Yajima, Akemi Kosaka, Takayuki Ohkuri, Kensuke Oikawa, Shohei Harabuchi, Michihisa Kono, Hidekiyo Yamaki, Risa Wakisaka, Yui Hirata-Nozaki, Kenzo Ohara, Takumi Kumai, Akihiro Katada, Tatsuya Hayashi, Yasuaki Harabuchi, Hiroya Kobayashi

    Cancer immunology, immunotherapy : CII   72 ( 7 )   2087 - 2098   2023年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The engagement of CD27 on lymphocytes with its ligand, CD70, on tumors is believed to mediate tumor immune evasion and the elevation of serum soluble CD27 (sCD27) levels in patients with CD70-positive malignancies. We previously showed that CD70 is expressed in extranodal natural killer/T-cell lymphoma, nasal type (ENKL), an Epstein-Barr virus (EBV)-related malignancy. However, little is known about serum sCD27 expression and its association with the clinical characteristics of, and the CD27/CD70 interaction in, ENKL. In the present study, we show that serum sCD27 is significantly elevated in the sera of patients with ENKL. The levels of serum sCD27 provided excellent diagnostic accuracy for discriminating patients with ENKL from healthy subjects, correlated positively with the levels of other diagnostic markers (lactate dehydrogenase, soluble interleukin-2 receptor, and EBV-DNA), and decreased significantly following treatment. Elevated serum sCD27 levels also correlated significantly with advanced clinical stage and tended to correspond with shorter survival, in patients with ENKL. Immunohistochemistry indicated that CD27-positive tumor-infiltrating immune cells exist adjacent to CD70-positive lymphoma cells. In addition, serum sCD27 levels in patients with CD70-positive ENKL were significantly higher than those in patients with CD70-negative ENKL, suggesting that the intra-tumoral CD27/CD70 interaction boosts the release of sCD27 in serum. Furthermore, the EBV-encoded oncoprotein latent membrane protein 1 upregulated CD70 expression in ENKL cells. Our results suggest that sCD27 may serve as a novel diagnostic biomarker and also may serve as a tool for evaluating the applicability of CD27/CD70-targeted therapies by predicting intra-tumoral CD70 expression and CD27/CD70 interaction in ENKL.

    DOI: 10.1007/s00262-023-03394-7

    PubMed

    researchmap

  • Mitogen-activated protein kinase inhibition augments the T cell response against HOXB7-expressing tumor through human leukocyte antigen upregulation. 査読 国際誌

    Hiroki Komatsuda, Risa Wakisaka, Michihisa Kono, Takumi Kumai, Ryusuke Hayashi, Hidekiyo Yamaki, Ryosuke Sato, Toshihiro Nagato, Takayuki Ohkuri, Akemi Kosaka, Kenzo Ohara, Miki Takahara, Akihiro Katada, Hiroya Kobayashi

    Cancer science   114 ( 2 )   399 - 409   2023年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Homeobox B7 (HOXB7) is a master regulatory gene that regulates cell proliferation and activates oncogenic pathways. Overexpression of HOXB7 correlates with aggressive behavior and poor prognosis in patients with cancer. However, the expression and role of HOXB7 in head and neck squamous cell carcinoma (HNSCC) remain unclear. In this study, we observed that most samples from patients with oropharyngeal cancer and HNSCC expressed HOXB7. As no direct inhibitor has been reported, we identified a potent peptide epitope to target HOXB7-expressing tumors through immune cells. A novel HOXB7-derived peptide epitope (HOXB78-25 ) elicited antigen-specific and tumor-reactive promiscuous CD4+ T cell responses. These CD4+ T cells produced γ-interferon (IFN-γ) and had the direct ability to kill tumors through granzyme B. Notably, downregulation of HOXB7 using siRNA enhanced human leukocyte antigen class II expression on tumor cells by decreasing the phosphorylation of MAPK. Mitogen-activated protein kinase inhibition augmented IFN-γ production by HOXB7-reactive CD4+ T cell responses without decreasing the expression of HOXB7. These results suggest that combining HOXB7 peptide-based vaccine with MAPK inhibitors could be an effective immunological strategy for cancer treatment.

    DOI: 10.1111/cas.15619

    PubMed

    researchmap

  • Tissue-resident memory CD8<SUP>+</SUP> T cells correlate with anti-PD-1 response in head and neck cancer and expand upon cDC1 activation in tumor-draining lymph nodes to overcome PD-1 resistance

    Michihisa Kono

    Clinical Cancer Research   2023年

     詳細を見る

    担当区分:筆頭著者   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1158/1557-3265.AACRAHNS23-PO-078

    Web of Science

    researchmap

  • The mouse oral carcinoma (MOC) model: A 10-year retrospective on model development and head and neck cancer investigations. 査読 国際誌

    Michihisa Kono, Shin Saito, Ann Marie Egloff, Clint T Allen, Ravindra Uppaluri

    Oral oncology   132   106012 - 106012   2022年9月

     詳細を見る

    担当区分:筆頭著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Preclinical models of cancer have long been paramount to understanding tumor development and advancing the treatment of cancer. Creating preclinical models that mimic the complexity and heterogeneity of human tumors is a key challenge in the advancement of cancer therapy. About ten years ago, we created the mouse oral carcinoma (MOC) cell line models that were derived from 7, 12-dimethylbenz(a) anthracene (DMBA)-induced mouse oral squamous cell cancers. This model has been used in numerous investigations, including studies on tumor biology and therapeutics. We have seen remarkable progress in cancer immunology in recent years, and these cell lines, which are syngeneic to C57BL/6 background, have also been used to study the anti-tumor immune response. Herein, we aim to review the MOC model from its development and characterization to its use in non-immunological and immunological preclinical head and neck squamous cell carcinoma (HNSCC) studies. Integrating and refining these MOC model studies and extending findings to other systems will provide crucial insights for translational approaches aimed at improving head and neck cancer treatment.

    DOI: 10.1016/j.oraloncology.2022.106012

    PubMed

    researchmap

  • A retrospective study of parotid gland tumors at a single institution. 査読 国際誌

    Shiori Suzuki, Nobuyuki Bandoh, Takashi Goto, Akinobu Kubota, Akihiro Uemura, Michihisa Kono, Ryosuke Sato, Ryuhei Takeda, Shota Sakaue, Tomomi Yamaguchi-Isochi, Hiroshi Nishihara, Hidehiro Takei, Yasuaki Harabuchi

    Oncology letters   24 ( 1 )   207 - 207   2022年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The aim of the present study was to analyze the clinical characteristics, surgical treatments and clinical outcome of patients with parotid gland tumors and to compare the results with those cited in the literature. A retrospective study was conducted in 140 patients (male, n=77; female, n=63) with parotid gland tumors who underwent parotidectomy at Hokuto Hospital Department of Otolaryngology-Head and Neck Surgery (Obihiro, Japan) between April 2007 and December 2021. Of the 140 patients enrolled, 118 (84.3%) patients had benign tumors, including 63 (45%) patients with pleomorphic adenomas and 43 (30.7%) patients with Warthin tumors, and 22 patients (15.7%) had parotid carcinoma. Comparison of the three groups of patients with parotid gland tumors indicated that pack years as an indicator of smoking status were significantly higher in patients with Warthin tumors than in those with parotid carcinomas (P=0.011) or pleomorphic adenoma (P<0.001). Fine-needle aspiration cytology (FNAC) was non-diagnostic for only 6 (4.3%) of 140 patients. The sensitivity, specificity, positive predictive value, negative predictive value and accuracy of FNAC by both conventional smear and liquid-based cytology (LBC) for parotid carcinomas were 70, 99, 93.3, 94.4 and 82.9%, respectively. Among the 22 patients with parotid carcinoma, extended total/total and superficial parotidectomy were performed in 10 (45%) and 11 (50%) cases, respectively. Total and selective neck dissection of the area from level II to I, II and III were performed in 6 (24%) and 7 (32%) patients, respectively. Postoperative radiotherapy (50 Gy) was performed in 15 (68%) patients. The overall survival (OS) and disease-free survival (DFS) rates at 5 years were 51.5 and 76.4%, respectively. Univariate analysis revealed that age >65 years was significantly associated with poorer 5-year OS (P<0.001) and DFS (P<0.001). Multivariate analysis revealed that an age of more than 65 years combined with high-grade histologic malignancy was associated with worse DFS (P=0.02; hazard ratio, 3.628; 95% confidence interval, 1.283-9.514). In conclusion, the clinical characteristics and treatment outcomes of parotid gland tumors were consistent with the results of previous reports. Smoking may be closely related to the pathogenesis of Warthin tumors. LBC potentially provides improved accuracy in FNAC.

    DOI: 10.3892/ol.2022.13328

    PubMed

    researchmap

  • IL-2 complex recovers steroid-induced inhibition in immunochemotherapy for head and neck cancer. 査読 国際誌

    Michihisa Kono, Hidekiyo Yamaki, Hiroki Komatsuda, Takumi Kumai, Ryusuke Hayashi, Risa Wakisaka, Ryosuke Sato, Kenzo Ohara, Kan Kishibe, Miki Takahara, Akihiro Katada, Tatsuya Hayashi, Yasuaki Harabuchi

    Translational oncology   18   101358 - 101358   2022年4月

     詳細を見る

    担当区分:筆頭著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: A combination therapy with immune checkpoint inhibitors (ICIs) and platinum-based chemotherapy has become the first-line treatment for recurrent or metastatic head and neck squamous carcinoma (HNSCC). Although steroids are often used as anti-emetic medications during chemotherapy, their adverse effects on immune-combined chemotherapy are unclear in HNSCC. METHODS: The effects of dexamethasone on tumor growth and immune cell population were evaluated in a mouse HNSCC model treated with PD-1 blockade combined with cisplatin. The effect of various doses of dexamethasone on cell proliferation, survival, surface markers, IFN-γ production, and antitumor effects in antigen-specific T cells was examined in vitro. The recovery of T cell dysfunction by IL-2 was assessed in vitro and in vivo. RESULTS: In a mouse HNSCC model, dexamethasone showed limited antitumor effects on immunochemotherapy. Dexamethasone decreased the number of T cells and inhibited T cell differentiation into effector and central memory T cells. In the in vitro assessment, dexamethasone induced cell death, limited proliferation, and reduced the reactivity against HNSCC cell lines of antigen-specific T cells in a dose-dependent manner. The expression of inhibitory receptors on T cells was not affected by steroids. This inhibition was recovered by IL-2 and IL-2/anti-IL-2 complexes (IL-2 Cx) in vitro and in vivo, respectively. CONCLUSION: Our preclinical data indicate that dexamethasone diminishes the antitumor effects of immunochemotherapy in patients with HNSCC. IL-2 Cx recovered the inhibition of antitumor immunity by steroids and might be a potent immune adjuvant for patients who require steroids during PD-1 blockade and chemotherapy.

    DOI: 10.1016/j.tranon.2022.101358

    PubMed

    researchmap

  • Antitumor Peptide-Based Vaccine in the Limelight. 査読 国際誌

    Takumi Kumai, Hidekiyo Yamaki, Michihisa Kono, Ryusuke Hayashi, Risa Wakisaka, Hiroki Komatsuda

    Vaccines   10 ( 1 )   2022年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The success of the immune checkpoint blockade has provided a proof of concept that immune cells are capable of attacking tumors in the clinic. However, clinical benefit is only observed in less than 20% of the patients due to the non-specific activation of immune cells by the immune checkpoint blockade. Developing tumor-specific immune responses is a challenging task that can be achieved by targeting tumor antigens to generate tumor-specific T-cell responses. The recent advancements in peptide-based immunotherapy have encouraged clinicians and patients who are struggling with cancer that is otherwise non-treatable with current therapeutics. By selecting appropriate epitopes from tumor antigens with suitable adjuvants, peptides can elicit robust antitumor responses in both mice and humans. Although recent experimental data and clinical trials suggest the potency of tumor reduction by peptide-based vaccines, earlier clinical trials based on the inadequate hypothesis have misled that peptide vaccines are not efficient in eliminating tumor cells. In this review, we highlighted the recent evidence that supports the rationale of peptide-based antitumor vaccines. We also discussed the strategies to select the optimal epitope for vaccines and the mechanism of how adjuvants increase the efficacy of this promising approach to treat cancer.

    DOI: 10.3390/vaccines10010070

    PubMed

    researchmap

  • Concurrent chemoradiotherapy with cisplatin and docetaxel for head and neck squamous cell carcinoma. 査読 国際誌

    Takumi Kumai, Hiroki Komatsuda, Risa Wakisaka, Hidekiyo Yamaki, Michihisa Kono, Ryusuke Hayashi, Kan Kishibe, Miki Takahara, Akihiro Katada, Tatsuya Hayashi, Yasuaki Harabuchi

    Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery   47 ( 1 )   228 - 233   2022年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1111/coa.13876

    PubMed

    researchmap

  • Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma. 査読 国際誌

    Michihisa Kono, Hiroki Komatsuda, Hidekiyo Yamaki, Takumi Kumai, Ryusuke Hayashi, Risa Wakisaka, Toshihiro Nagato, Takayuki Ohkuri, Akemi Kosaka, Kenzo Ohara, Kan Kishibe, Miki Takahara, Akihiro Katada, Tatsuya Hayashi, Hiroya Kobayashi, Yasuaki Harabuchi

    Oncoimmunology   11 ( 1 )   2021619 - 2021619   2022年

     詳細を見る

    担当区分:筆頭著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Fibroblast growth factor receptor 1 (FGFR1) is overexpressed in multiple types of solid tumors, including head and neck squamous cell carcinoma (HNSCC). Being associated with poor prognosis, FGFR1 is a potential therapeutic target for aggressive tumors. T cell-based cancer immunotherapy has played a central role in novel cancer treatments. However, the potential of antitumor immunotherapy targeting FGFR1 has not been investigated. Here, we showed that FGFR-tyrosine kinase inhibitors (TKIs) augmented antitumor effects of immune checkpoint inhibitors in an HNSCC mouse model and upregulated tumoral MHC class I and MHC class II expression in vivo and in vitro. This upregulation was associated with the mitogen-activated protein kinase signaling pathway, which is a crucial pathway for cancer development through FGFR signaling. Moreover, we identified an FGFR1-derived peptide epitope (FGFR1305-319) that could elicit antigen-reactive and multiple HLA-restricted CD4+ T cell responses. These T cells showed direct cytotoxicity against tumor cells that expressed FGFR1. Notably, FGFR-TKIs augmented antitumor effects of FGFR1-reactive T cells against human HNSCC cells. These results indicate that the combination of FGFR-TKIs with immunotherapy, such as an FGFR1-targeting peptide vaccine or immune checkpoint inhibitor, could be a novel and robust immunologic approach for treating patients with FGFR1-expressing cancer cells.

    DOI: 10.1080/2162402X.2021.2021619

    PubMed

    researchmap

  • Peptide-reactive T cell response as a novel biomarker in head and neck cancer patients treated with anti-PD-1 antibody 査読

    Michihisa Kono

    Cancer Science   2022年

     詳細を見る

    掲載種別:研究論文(学術雑誌)  

    Web of Science

    researchmap

  • Interruption of MDM2 signaling augments MDM2-targeted T cell-based antitumor immunotherapy through antigen-presenting machinery. 査読 国際誌

    Michihisa Kono, Takumi Kumai, Ryusuke Hayashi, Hidekiyo Yamaki, Hiroki Komatsuda, Risa Wakisaka, Toshihiro Nagato, Takayuki Ohkuri, Akemi Kosaka, Kenzo Ohara, Kan Kishibe, Miki Takahara, Akihiro Katada, Tatsuya Hayashi, Esteban Celis, Hiroya Kobayashi, Yasuaki Harabuchi

    Cancer immunology, immunotherapy : CII   70 ( 12 )   3421 - 3434   2021年12月

     詳細を見る

    担当区分:筆頭著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Identification of immunogenic tumor antigens, their corresponding T cell epitopes and the selection of effective adjuvants are prerequisites for developing effective cancer immunotherapies such as therapeutic vaccines. Murine double minute 2 (MDM2) is an E3 ubiquitin-protein ligase that negatively regulates tumor suppressor p53. Because MDM2 overexpression serves as a poor prognosis factor in various types of tumors, it would be beneficial to develop MDM2-targeted cancer vaccines. In this report, we identified an MDM2-derived peptide epitope (MDM232-46) that elicited antigen-specific and tumor-reactive CD4+ T cell responses. These CD4+ T cells directly killed tumor cells via granzyme B. MDM2 is expressed in head and neck cancer patients with poor prognosis, and the T cells that recognize this MDM2 peptide were present in these patients. Notably, Nutlin-3 (MDM2-p53 blocker), inhibited tumor cell proliferation, was shown to augment antitumor T cell responses by increasing MDM2 expression, HLA-class I and HLA-DR through class II transactivator (CIITA). These results suggest that the use of this MDM2 peptide as a therapeutic vaccine combined with MDM2 inhibitors could represent an effective immunologic strategy to treat cancer.

    DOI: 10.1007/s00262-021-02940-5

    PubMed

    researchmap

  • Endoscopic Endonasal and Transmaxillary Approach for Resection of Juvenile Nasopharyngeal Angiofibroma With Preoperative Embolization in a Child. 査読

    Michihisa Kono

    The Journal of craniofacial surgery   2021年7月

     詳細を見る

    掲載種別:研究論文(学術雑誌)  

    <h4>Abstract</h4>A 13-year-old Japanese boy with a 6-month history of bilateral nasal obstruction and a 3-week history of recurrent epistaxis from the right nose was admitted to our department. Nasal endoscopy revealed a reddish, smooth-walled tumor occupying the right nasal cavity. Computed tomography scan revealed a 3.5 × 4.5 × 7.0-cm heterogeneously enhancing mass involving the right nasal cavity and extending posteriorly to the nasopharynx, and laterally to the pterygopalatine fossa and the medial part of the infratemporal fossa. We diagnosed as juvenile nasopharyngeal angiofibroma with Radkowski classification stage IIC. The internal maxillary and ascending pharyngeal arteries were embolized with polyvinyl alcohol followed by Embosphere using a conventional Seldinger technique. En bloc resection was performed with an endoscopic ipsilateral endonasal and sublabial Caldwell-Luc transmaxillary approach under general anesthesia. As of 3 years postoperatively, no recurrence has been found. We report a child case of juvenile nasopharyngeal angiofibroma successfully treated with less invasive surgery with preoperative embolization.

    DOI: 10.1097/scs.0000000000007495

    DOI: 10.1097/SCS.0000000000007495

    PubMed

    researchmap

  • Effects of early nutritional intervention by a nutritional support team for patients with head and neck cancer undergoing chemoradiotherapy or radiotherapy. 査読 国際誌

    Michihisa Kono, Risa Wakisaka, Takumi Kumai, Ryusuke Hayashi, Hiroki Komatsuda, Ryosuke Sato, Yasushi Abe, Hidekiyo Yamaki, Miki Takahara, Akihiro Katada, Tatsuya Hayashi, Yasuaki Harabuchi

    Head & neck   43 ( 2 )   514 - 519   2021年2月

     詳細を見る

    担当区分:筆頭著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: We analyzed the effects of early nutritional intervention by a nutritional support team (NST) in patients with head and neck squamous cell carcinoma (HNSCC) undergoing chemoradiotherapy or radiotherapy. METHODS: This study investigated whether early nutritional interventions by a multidisciplinary NST improve body weight loss, mucositis, serum albumin level, and hospital length of stay. RESULTS: Sixty-one patients with HNSCC were treated during the study, and 32 patients received NST intervention since admission. The median weight loss rates were 3.3% and 7.3% and grade 3 mucositis was observed in 25.0% and 70.0% of patients in the intervention and nonintervention groups, respectively. In the intervention group, serum albumin level through treatment increased and the hospital length of stay from the end of treatment was shortened. CONCLUSION: Early nutritional intervention by a multidisciplinary NST improved body weight loss rate, mucositis, albumin level, and hospital length of stay, which might lead to better clinical outcomes.

    DOI: 10.1002/hed.26502

    PubMed

    researchmap

  • Clinical Study of 107 Hospitalized Patients with Peritonsillar Abscess 査読

    Risa Wakisaka, Takumi Kumai, Kan Kishibe, Miki Takahara, Akihiro Katada, Tatsuya Hayashi, Yasuaki Harabuchi

    International Journal of Practical Otolaryngology   04 ( 01 )   e11 - e16   2021年1月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:Georg Thieme Verlag KG  

    Abstract

    We conducted a retrospective analysis of the data of 107 cases of peritonsillar abscess treated at our hospital between January 2014 and December 2018. Data on age, sex, affected site, duration of hospitalization, method of drainage, presence/absence of laryngeal edema, antibacterial drugs used, and isolated bacteria were analyzed. Of the 107 patients, 71 were males and 36 were females; the median age was 44 years (range: 18–88 years).The left side was affected in 55 patients, the right side in 50 patients, and both sides in two patients. The abscess was localized in the superior pole in 71 patients, and in the inferior pole in 36 patients. Thirty-five patients had laryngeal edema, of which three underwent tracheotomy. Recurrence of the abscess was observed in 15 cases, with the recurrence developing within 3 months in 7 cases, and over a period of 3 years in 4 cases. As for the sensitivity of the causative bacteria to antibacterial drugs, 17% of the causative bacteria showed resistance to clindamycin, while none showed resistance to ampicillin/sulbactam (ABPC/SBT). We concluded that ABPC/SBT might be suitable for the initial treatment of peritonsillar abscess, and that we need to bear in mind the possibility of long-term recurrence.

    DOI: 10.1055/s-0041-1722857

    researchmap

  • Peripherally Inserted Central Venous Catheters Provide Safe and Easy Central Venous Access in Patients with Head and Neck Cancer 査読

    Ryosuke Sato, Takumi Kumai, Ryusuke Hayashi, Hiroki Komatsuda, Kan Kishibe, Miki Takahara, Akihiro Katada, Tatsuya Hayashi, Yasuaki Harabuchi

    International Journal of Practical Otolaryngology   04 ( 01 )   e29 - e33   2021年1月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:Georg Thieme Verlag KG  

    Abstract

    Purpose The use of peripherally inserted central venous catheters (PICCs) has increased recently; several reports have revealed that they can be easily and safely used in patients with various diseases. However, there are few reports on the use of PICCs in patients with head and neck cancer. This study was aimed at evaluating the safety and feasibility of use of PICCs in patients with head and neck cancer.

    Materials and Methods We retrospectively analyzed the date of 118 PICC insertions in 85 patients with head and neck cancer from January 2014 to December 2017. The PICCs have been placed under ultrasound guidance in all cases.

    Results The PICC puncture success rate was 95.2%. Catheter-related bloodstream infection occurred in four cases. The most common complication necessitating PICC removal was suspected catheter-related bloodstream infection (24 cases). All cases with confirmed and suspected catheter-related bloodstream infection improved with administration of antimicrobial agents. Phlebitis occurred in five cases, in all of whom the PICC placement had been made via an antecubital vein; the condition improved without treatment in all five cases. Deep vein thrombosis occurred in two cases, both of which improved with oral anticoagulant therapy.

    Conclusion This study demonstrated that the complications associated with ultrasound-guided PICC insertion are manageable, and improve with conservative treatment in the majority of cases. Therefore, use of PICCs may be considered for easy and safe central venous access in patients with head and neck cancer, because the insertion success rate was acceptable.

    DOI: 10.1055/s-0041-1728747

    researchmap

  • Expression of placenta-specific 1 and its potential for eliciting anti-tumor helper T-cell responses in head and neck squamous cell carcinoma. 査読 国際誌

    Ryusuke Hayashi, Toshihiro Nagato, Takumi Kumai, Kenzo Ohara, Mizuho Ohara, Takayuki Ohkuri, Yui Hirata-Nozaki, Shohei Harabuchi, Akemi Kosaka, Marino Nagata, Yuki Yajima, Syunsuke Yasuda, Kensuke Oikawa, Michihisa Kono, Kan Kishibe, Miki Takahara, Akihiro Katada, Tatsuya Hayashi, Esteban Celis, Yasuaki Harabuchi, Hiroya Kobayashi

    Oncoimmunology   10 ( 1 )   1856545 - 1856545   2020年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Placenta-specific 1 (PLAC1) is expressed primarily in placental trophoblasts but not in normal tissues and is a targetable candidate for cancer immunotherapy because it is a cancer testis antigen known to be up-regulated in various tumors. Although peptide epitopes capable of stimulating CD8 T cells have been previously described, there have been no reports of PLAC1 CD4 helper T lymphocyte (HTL) epitopes and the expression of this antigen in head and neck squamous cell carcinoma (HNSCC). Here, we show that PLAC1 is highly expressed in 74.5% of oropharyngeal and 51.9% of oral cavity tumors from HNSCC patients and in several HNSCC established cell lines. We also identified an HTL peptide epitope (PLAC131-50) capable of eliciting effective antigen-specific and tumor-reactive T cell responses. Notably, this peptide behaves as a promiscuous epitope capable of stimulating T cells in the context of more than one human leukocyte antigen (HLA)-DR allele and induces PLAC1-specific CD4 T cells that kill PLAC1-positive HNSCC cell lines in an HLA-DR-restricted manner. Furthermore, T-cells reactive to PLAC131-50 peptide were detected in the peripheral blood of HNSCC patients. These findings suggest that PLAC1 represents a potential target antigen for HTL based immunotherapy in HNSCC.

    DOI: 10.1080/2162402X.2020.1856545

    PubMed

    researchmap

  • Glomangiopericytoma of the Nasal Cavity with CTNNB1 p.S37C Mutation: A Case Report and Literature Review. 査読 国際誌

    Michihisa Kono, Nobuyuki Bandoh, Ryosuke Matsuoka, Takashi Goto, Toshiaki Akahane, Yasutaka Kato, Hiroshi Nakano, Tomomi Yamaguchi, Yasuaki Harabuchi, Hiroshi Nishihara

    Head and neck pathology   13 ( 3 )   298 - 303   2019年9月

     詳細を見る

    担当区分:筆頭著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Glomangiopericytoma (GPC) is a rare mesenchymal tumor arising from the nasal cavity or paranasal sinuses. GPC was categorized as a borderline and low-malignant-potential tumor by the World Health Organization in 2005 and accounts for less than 0.5% of all sinonasal tumors. We report a case of GPC in a 74-year-old woman with a history of recurrent epistaxis and nasal obstruction. A reddish tumor was seen in the right nasal cavity. Enhanced computed tomography showed a mass lesion occupying the right nasal cavity. The tumor, which originated from the nasal septum in the olfactory fissure area, was resected with 5-mm mucosal margins by endoscopic sinus surgery. Histologic examination revealed a uniform proliferation of oval-to-short spindle-shaped cells beneath the epithelium. Immunohistologic analysis demonstrated the tumor cells were positive for α-smooth muscle actin, β-catenin and Vimentin, and negative for AE1/AE3, Bcl-2, CD34, CD117, Factor VIIIR Ag, S-100 protein, or STAT6. The percentage of Ki-67-positive cells was approximately 5%. Genetic analysis using next-generation sequencing revealed a missense mutation in the CTNNB1 gene (c.110C > G, p.S37C). While other CTNNB1 mutations have been described in GPC; this is the first report of this specific mutation. The mutation was confirmed using Sanger sequencing.

    DOI: 10.1007/s12105-018-0961-z

    PubMed

    researchmap

  • Lung Adenocarcinoma with Cheek Dysesthesia as an Initial Symptom: A Case Report and Literature Review. 査読 国際誌

    Nobuyuki Bandoh, Haruyuki Ichikawa, Atsuyoshi Asahi, Michihisa Kono, Shohei Harabuchi, Ryosuke Sato, Akihiro Uemura, Takashi Goto, Tomomi Yamaguchi, Yasutaka Kato, Hironori Furukawa, Hidehiro Takei, Yasuaki Harabuchi

    Case reports in oncology   12 ( 2 )   650 - 656   2019年

     詳細を見る

    記述言語:英語  

    Metastasis from lung carcinoma to the sphenoid bone is rare. Patients with symptoms related to sphenoid bone metastasis as the initial presentation of carcinoma are thus also rare. Herein, we report the case of a patient presenting with only cheek dysesthesia as the first sign of lung adenocarcinoma. The 74-year-old woman presented with a 2-month history of left cheek dysesthesia. CT showed a tumor around 2.5 cm in diameter with heterogeneous enhancement of the central focus at the left foramen rotundum in the sphenoid bone. We endoscopically biopsied the tumor through the left sphenoid sinus. Results of histologic examination were consistent with lung adenocarcinoma. FDG-PET/CT analysis demonstrated lung carcinoma that had already metastasized to mediastinal lymph nodes and multiple bones, such as the ribs and lumbar vertebras, in addition to the sphenoid bone. As EGFR gene mutation (p.L858R) was identified, the patient was treated with oral gefinitib. This treatment proved quite effective, and the patient remains alive without tumor growth as of 18 months.

    DOI: 10.1159/000502053

    PubMed

    researchmap

  • Targeted next-generation sequencing of cancer-related genes in thyroid carcinoma: A single institution's experience. 査読 国際誌

    Nobuyuki Bandoh, Toshiaki Akahane, Takashi Goto, Michihisa Kono, Haruyuki Ichikawa, Takahiro Sawada, Tomomi Yamaguchi, Hiroshi Nakano, Yumiko Kawase, Yasutaka Kato, Hajime Kamada, Yasuaki Harabuchi, Kazuo Shimizu, Hiroshi Nishihara

    Oncology letters   16 ( 6 )   7278 - 7286   2018年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Thyroid carcinoma (TC) has characteristic genetic alterations, including point mutations in proto-oncogenes and chromosomal rearrangements that vary by histologic subtype. Recent developments in next-generation sequencing (NGS) technology enable simultaneous analysis of cancer-associated genes of interest, thus improving diagnostic accuracy and allowing precise personalized treatment for human cancer. A total of 50 patients who underwent thyroidectomy between 2014 and 2016 at Hokuto Hospital were enrolled. Total DNA was extracted from formalin-fixed, paraffin-embedded tissue sections and quantified. Targeted regions of 24 cancer-associated genes were amplified by PCR, barcoded and sequenced using an Illumina MiSeq platform. Subjects included 30 patients with papillary carcinoma (PC), two with PC tall cell variant (TVPC), two with PC follicular variant (FVPC), eight with follicular carcinoma, seven with poorly differentiated carcinoma (PDC), and one with anaplastic carcinoma (AC). The BRAF V600E mutation was present in 25 of 30 (83%) patients with PC, 2 of 2 (100%) patients with TVPC, 6 of 7 (86%) patients of PDC, and one patient with AC. PIK3CA mutations were present in 3 of 30 (delPV104P, A1046T and C420R; 10%) patients with PC and 1 of 7 (H1047R; 14%) patients with PDC. The TP53 mutation was present in 1 of 30 (R306*; 3.3%) patients with PC and 1 of 7 (Q152*; 14%) patients with PDC. The NRAS mutation was present in 1 of 2 (Q61K, 50%) patients with FVPC. Statistical analysis showed that patients without the BRAF V600E mutation had advanced pathologic T and N stages compared with those with the mutation (P=0.047 and P=0.019, respectively). The BRAF V600E mutation was not correlated with overall and disease-free survival in patients with PC. A patient with PC with a mutation in EGFR (K852Q) and the PIK3CA mutation had an aggressive course with multiple bone and lung metastases. Detection of mutations in cancer-associated genes using NGS could enhance the understanding of the clinical behavior of TC.

    DOI: 10.3892/ol.2018.9538

    PubMed

    researchmap

  • A Clinical Study of Patients with Acute Epiglottitis 査読

    Michihisa Kono, Takashi Goto, Nobuyuki Bandoh, Yasuaki Harabuchi

    International Journal of Practical Otolaryngology   01 ( 01 )   e1 - e5   2018年6月

     詳細を見る

    担当区分:筆頭著者   掲載種別:研究論文(学術雑誌)   出版者・発行元:Georg Thieme Verlag KG  

    Abstract

    Acute epiglottitis is an acute inflammation of the upper respiratory airway that rarely causes airway obstruction. A retrospective study was conducted on 115 patients with acute epiglottitis from April 2007 to December 2017 (65 males and 50 females; aged 12–85 years old, median age of 45 years). When counting the number of patients according to the month, from April to September more than 10 patients were treated. Median duration from symptom onset to first visit was 3 days (1–14 days). Eight (7%) of 115 patients had diabetes, and 16 (13.9%) had epiglottic cyst. We divided all the patients into six groups by laryngeal findings according to the classification of Katori and Tsukuda. Number of patients classified as IA, IB, IIA, IIB, IIIA, and IIIB was 41 (35.7%), 21 (18.3%), 22 (19.1%), 15 (13%), 8 (7%), and 8 (7%), respectively. Median duration of hospitalization was 5 days (2–26 days). In the blood test on the first day of hospitalization, the number of white blood cells (WBC) ranged from 3,400 to 25,350/μL (median 10,350/μL) and the C-reactive protein (CRP) ranged from 0.01 to 23.3 mg/dL (median, 2.5 mg/dL). The number of WBC and CRP at the fourth day after the hospitalization was significantly lower than those at the first day. Eight (7%) patients required the airway management such as tracheotomy or cricothyroidotomy. Age, laryngeal finding (severe epiglottis swelling and arytenoid edema; Katori and Tsukuda's classification IIIB), and high inflammatory reaction in blood test (WBC ≥ 20,000/μL and CRP ≥ 20 mg/dL) were the factors that significantly correlated with the airway management.

    DOI: 10.1055/s-0038-1660522

    researchmap

  • 進行頭頸部扁平上皮癌に対し、放射線併用超選択的動注化学療法を施行した症例の検討 査読

    坂東 伸幸, 後藤 孝, 河野 通久, 宮本 顕彦, 西尾 明正

    頭頸部癌   43 ( 2 )   272 - 272   2017年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本頭頸部癌学会  

    researchmap

  • 広範囲胸壁浸潤をきたした甲状腺濾胞癌縦隔リンパ節転移 査読

    河野 通久, 野村 研一郎, 北田 正博, 片田 彰博, 林 達哉, 原渕 保明

    日本気管食道科学会会報   68 ( 2 )   s70 - s70   2017年4月

     詳細を見る

    担当区分:筆頭著者   記述言語:日本語   出版者・発行元:(NPO)日本気管食道科学会  

    researchmap

  • ANCA-Negative Granulomatosis with Polyangiitis Presenting with Hypertrophic Cranial Pachymeningitis, Abducens Nerve Palsy, and Stenosis of the Internal Carotid Artery. 査読 国際誌

    Shohei Harabuchi, Nobuyuki Bandoh, Rika Yasukawa, Michihisa Kono, Takashi Goto, Yasuaki Harabuchi, Hidetoshi Ikeda, Hajime Kamada, Hiroshi Nishihara

    Case reports in otolaryngology   2017   9687383 - 9687383   2017年

     詳細を見る

    記述言語:英語  

    We report a rare case of granulomatosis with polyangiitis (GPA) presenting with hypertrophic cranial pachymeningitis (HCP), abducens nerve palsy, and stenosis of the internal carotid artery (ICA). A 59-year-old Japanese man presented with a year history of nasal obstruction and a 2-month history of slight headache. Histopathological examination of the granulomatous mucosa in the ethmoid sinuses resected by endoscopic sinus surgery revealed necrotizing vasculitis with multinucleated giant cells. The patient was diagnosed with the limited form of GPA as a result of the systemic examination. He declined immunosuppressive treatment. Eighteen months after the diagnosis of GPA, he presented with diplopia and severe headache. Though nasal findings indicating GPA were not observed in the nasal cavity, CT scan revealed a lesion of the right sphenoid sinus eroding the bone of the clivus. Gadolinium-enhanced MRI of the brain showed thickening of the dura mater around the right cavernous sinus and clivus. Magnetic resonance angiography and cerebral angiography revealed narrowing at the C5 portion of the ICA. Intravenous methylprednisolone pulse therapy followed by oral prednisolone and cyclophosphamide resolved headache and dramatically improved HCP and stenosis of the ICA.

    DOI: 10.1155/2017/9687383

    PubMed

    researchmap

▼全件表示

MISC

  • Expression of soluble CD27 in nasopharyngeal carcinoma: potential as a biomarker for intratumoral CD70/CD27 interaction

    Toshihiro Nagato, Hiroki Komatsuda, Ryusuke Hayashi, Nanami Ujiie, Akemi Kosaka, Takayuki Ohkuri, Takahiro Inoue, Ryosuke Sato, Risa Wakisaka, Michihisa Kono, Hidekiyo Yamaki, Kenzo Ohara, Takumi Kumai, Kan Kishibe, Miki Takahara, Hiroya Kobayashi

    CANCER SCIENCE   116   984 - 984   2025年1月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)  

    Web of Science

    researchmap

  • 当科における10年間の内視鏡下(VANS)も含めた副甲状腺手術症例の検討

    石田 芳也, 湯浅 諒汰, 和田 哲治, 河野 通久, 道塚 智彦, 藤原 智貴, 久保田 瑛進, 荒木 大輔, 佐藤 遼介, 宮越 薫, 寒風澤 知明

    日本耳鼻咽喉科頭頸部外科学会会報   127 ( 4 )   591 - 591   2024年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本耳鼻咽喉科頭頸部外科学会  

    researchmap

  • 頭頸部扁平上皮癌におけるBrachyury特異的T細胞による抗腫瘍効果の検討(Antitumor effect of Brachyury-specific T cells in squamous cell carcinoma of the head and neck)

    山木 英聖, 熊井 琢美, 脇坂 理紗, 小松田 浩樹, 河野 通久, 林 隆介, 大原 賢三, 長門 利純, 小坂 朱, 大栗 敬幸, 岸部 幹, 高原 幹, 小林 博也

    日本癌学会総会記事   82回   578 - 578   2023年9月

     詳細を見る

    記述言語:英語   出版者・発行元:(一社)日本癌学会  

    researchmap

  • 節外性NK/T細胞リンパ腫、鼻型における可溶性CD27の発現(Expression of soluble CD27 in extranodal natural killer/T-cell lymphoma, nasal type)

    長門 利純, 小松田 浩樹, 林 隆介, 高原 幹, 岸部 幹, 小坂 朱, 大栗 敬幸, 及川 賢輔, 河野 通久, 山木 英聖, 脇坂 理紗, 大原 賢三, 熊井 琢美, 片田 彰博, 原渕 保明, 小林 博也

    日本癌学会総会記事   82回   1888 - 1888   2023年9月

     詳細を見る

    記述言語:英語   出版者・発行元:(一社)日本癌学会  

    researchmap

  • 腫瘍関連抗原を標的としたSyngenic頭頸部癌ワクチンモデルの開発

    熊井 琢美, 河野 通久, 山木 英聖, 小松田 浩樹, 脇坂 理紗, 林 隆介, 大原 賢三, 高原 幹, 片田 彰博, 林 達哉

    日本耳鼻咽喉科免疫アレルギー感染症学会抄録集   3回   224 - 224   2023年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本耳鼻咽喉科免疫アレルギー感染症学会  

    researchmap

  • 頭頸部扁平上皮癌におけるBrachyuryの発現とBrachyury特異的T細胞による抗腫瘍効果の検討(Antitumor effect of Brachyury-specific T cells in squamous cell carcinoma of the head and neck)

    山木 英聖, 熊井 琢美, 小松田 浩樹, 河野 通久, 大原 賢三, 岸部 幹, 高原 幹

    日本癌学会総会記事   81回   P - 2233   2022年9月

     詳細を見る

    記述言語:英語   出版者・発行元:(一社)日本癌学会  

    researchmap

  • 頭頸部扁平上皮癌におけるPLAC1の発現およびPLAC1特異的ヘルパーT細胞の抗腫瘍効果に関する検討(Expression of PLAC1 and its potential for eliciting anti-tumor helper T-cell responses in HNSCC)

    長門 利純, 林 隆介, 熊井 琢美, 大原 賢三, 大栗 敬幸, 野崎 結, 原渕 翔平, 小坂 朱, 矢島 優己, 安田 俊輔, 及川 賢輔, 河野 通久, 岸部 幹, 高原 幹, 原渕 保明, 小林 博也

    日本癌学会総会記事   81回   P - 1288   2022年9月

     詳細を見る

    記述言語:英語   出版者・発行元:(一社)日本癌学会  

    researchmap

  • 乳癌に対するS-1投与中に発症した鼻涙管閉塞例

    大湊 久貴, 河野 通久, 山木 英聖, 熊井 琢美, 高原 幹, 片田 彰博, 林 達哉

    耳鼻咽喉科臨床   115 ( 6 )   503 - 506   2022年6月

  • HOXB7を標的としたペプチドワクチン療法の開発

    小松田 浩樹, 長門 利純, 河野 通久, 山木 英聖, 脇坂 理紗, 熊井 琢美, 岸部 幹, 高原 幹, 片田 彰博, 林 達哉, 原渕 保明

    日本耳鼻咽喉科頭頸部外科学会会報   125 ( 4 )   759 - 759   2022年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本耳鼻咽喉科頭頸部外科学会  

    researchmap

  • シラカバ花粉PFASマウスモデルによる疾患発症機序の解析

    大原 賢三, 熊井 琢美, 山木 英聖, 河野 通久, 脇坂 理紗, 高原 幹, 片田 彰博, 林 達哉, 原渕 保明

    日本耳鼻咽喉科免疫アレルギー感染症学会抄録集   2回   180 - 180   2022年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本耳鼻咽喉科免疫アレルギー感染症学会  

    researchmap

  • 頭頸部癌におけるPEG10を標的としたペプチドワクチン療法の開発

    小松田 浩樹, 長門 利純, 河野 通久, 山木 英聖, 脇坂 理紗, 熊井 琢美, 岸部 幹, 高原 幹, 片田 彰博, 林 達哉, 小林 博也, 原渕 保明

    日本耳鼻咽喉科免疫アレルギー感染症学会抄録集   2回   160 - 160   2022年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本耳鼻咽喉科免疫アレルギー感染症学会  

    researchmap

  • 頭頸部扁平上皮癌に対するFGFR1を標的としたがん免疫療法

    脇坂 理紗, 熊井 琢美, 河野 通久, 小松田 浩樹, 山木 英聖, 岸部 幹, 高原 幹, 片田 彰博, 林 達哉, 原渕 保明

    日本耳鼻咽喉科免疫アレルギー感染症学会抄録集   2回   159 - 159   2022年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本耳鼻咽喉科免疫アレルギー感染症学会  

    researchmap

  • 頭頸部癌におけるBrachyuryを標的としたペプチドワクチン療法の検討

    山木 英聖, 熊井 琢美, 脇坂 理紗, 小松田 浩樹, 河野 通久, 大原 賢三, 岸部 幹, 高原 幹, 片田 彰博, 林 達哉, 原渕 保明

    日本耳鼻咽喉科免疫アレルギー感染症学会抄録集   2回   145 - 145   2022年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本耳鼻咽喉科免疫アレルギー感染症学会  

    researchmap

  • ペプチドを用いた免疫チェックポイント阻害薬のバイオマーカー探索

    熊井 琢美, 山木 英聖, 河野 通久, 脇坂 理紗, 大原 賢三, 岸部 幹, 高原 幹, 片田 彰博, 林 達哉, 原渕 保明

    日本耳鼻咽喉科免疫アレルギー感染症学会抄録集   2回   85 - 85   2022年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本耳鼻咽喉科免疫アレルギー感染症学会  

    researchmap

  • 鼻副鼻腔腫瘍におけるがん遺伝子パネル検査

    坂東 伸幸, 後藤 孝, 上村 明寛, 久保田 瑛進, 朝日 淳仁, 加藤 容崇, 佐藤 遼介, 河野 通久

    日本鼻科学会会誌   60 ( 3 )   410 - 410   2021年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本鼻科学会  

    researchmap

  • 鼻副鼻腔に発生したGlomangiopericytomaの5例

    寒風澤 知明, 熊井 琢美, 河野 通久, 道塚 智彦, 岸部 幹, 高原 幹, 片田 彰博, 林 達哉, 原渕 保明

    日本鼻科学会会誌   60 ( 3 )   347 - 347   2021年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本鼻科学会  

    researchmap

  • MDM2シグナル伝達阻害は抗原提示機構を介してMDM2を標的とした抗腫瘍免疫療法を増強する

    河野 通久, 熊井 琢美, 林 隆介, 山木 英聖, 大原 賢三, 岸部 幹, 高原 幹, 片田 彰博, 林 達哉, 原渕 保明

    日本癌学会総会記事   80回   [P12 - 2]   2021年9月

     詳細を見る

    記述言語:英語   出版者・発行元:(一社)日本癌学会  

    researchmap

  • 腫瘍抗原ペプチドを用いた免疫チェックポイント阻害薬におけるバイオマーカー探索

    熊井 琢美, 林 隆介, 河野 通久, 山木 英聖, 野崎 結, 大原 賢三, 岸部 幹, 高原 幹, 片田 彰博, 林 達哉, 原渕 保明

    日本癌学会総会記事   80回   [E12 - 5]   2021年9月

     詳細を見る

    記述言語:英語   出版者・発行元:(一社)日本癌学会  

    researchmap

  • MDM2を標的としたがんペプチドワクチン療法の基礎的解析

    河野 通久, 熊井 琢美, 林 隆介, 山木 英聖, 長門 利純, 林 達哉, 小林 博也, 原渕 保明

    日本耳鼻咽喉科免疫アレルギー感染症学会抄録集   1回   137 - 137   2021年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本耳鼻咽喉科免疫アレルギー感染症学会  

    researchmap

  • 頭頸部扁平上皮癌におけるplacenta-specific 1(PLAC1)の発現とPLAC1特異的ヘルパーT細胞における抗腫瘍効果の検討

    長門 利純, 林 隆介, 熊井 琢美, 大原 賢三, 野崎 結, 原渕 翔平, 河野 通久, 山木 英聖, 岸部 幹, 高原 幹, 片田 彰博, 林 達哉, 原渕 保明, 小林 博也

    日本耳鼻咽喉科免疫アレルギー感染症学会抄録集   1回   137 - 137   2021年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本耳鼻咽喉科免疫アレルギー感染症学会  

    researchmap

  • SMARCB1欠損篩骨洞未分化癌の一例

    道塚 智彦, 河野 通久, 寒風澤 知明, 熊井 琢美, 高原 幹, 片田 彰博, 林 達哉, 原渕 保明

    頭頸部癌   47 ( 2 )   224 - 224   2021年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本頭頸部癌学会  

    researchmap

  • 当科における喉頭乳頭腫症例の検討

    片田 彰博, 小口 亜莉沙, 河野 通久, 道塚 智彦, 寒風澤 知明, 野崎 結, 山木 英聖, 熊井 琢美, 岸部 幹, 高原 幹, 林 達哉, 原渕 保明

    日本耳鼻咽喉科学会会報   124 ( 4 )   570 - 570   2021年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本耳鼻咽喉科頭頸部外科学会  

    researchmap

  • 頭頸部癌に対するMDM2-p53を標的としたがん免疫療法

    河野 通久, 熊井 琢美, 林 隆介, 山木 英聖, 岸部 幹, 高原 幹, 片田 彰博, 林 達哉, 原渕 保明

    日本耳鼻咽喉科学会会報   124 ( 4 )   595 - 595   2021年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本耳鼻咽喉科頭頸部外科学会  

    researchmap

  • 融合遺伝子ETV6-Xを認めた顎下腺分泌癌例

    河野 通久, 石田 芳也, 和田 哲治, 熊井 琢美, 長門 利純, 片岡 俊朗, 加藤 生真, 西原 弘治, 小林 博也, 原渕 保明

    耳鼻咽喉科臨床   113 ( 12 )   787 - 792   2020年12月

  • 頬部に発生した未分化癌の1例

    荒木 大輔, 和田 哲治, 石田 芳也, 河野 通久, 原渕 保明

    耳鼻咽喉科臨床 補冊   ( 補冊155 )   142 - 142   2020年12月

     詳細を見る

    記述言語:日本語   出版者・発行元:耳鼻咽喉科臨床学会  

    researchmap

  • 気管切開を要した後天性血友病Aの1例

    小川 弘記, 河野 通久, 久保田 瑛進, 荒木 大輔, 石田 芳也, 和田 哲治, 原渕 保明

    耳鼻咽喉科臨床 補冊   ( 補冊155 )   138 - 138   2020年12月

     詳細を見る

    記述言語:日本語   出版者・発行元:耳鼻咽喉科臨床学会  

    researchmap

  • 涙嚢鼻腔吻合術を施行したTS-1による鼻涙管閉塞症の1例

    大湊 久貴, 河野 通久, 山木 英聖, 熊井 琢美, 岸部 幹, 高原 幹, 片田 彰博, 林 達哉, 原渕 保明

    日本鼻科学会会誌   59 ( Suppl. )   S35 - S35   2020年12月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本鼻科学会  

    researchmap

  • 頭頸部扁平上皮癌におけるPLAC1の発現とPLAC1特異的T細胞による抗腫瘍効果の検討

    林 隆介, 長門 利純, 熊井 琢美, 河野 通久, 原渕 翔平, 岸部 幹, 高原 幹, 片田 彰博, 林 達哉, 小林 博也, 原渕 保明

    頭頸部癌   46 ( 2 )   147 - 147   2020年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本頭頸部癌学会  

    researchmap

  • 当科における唾液腺導管癌症例の検討

    河野 通久, 石田 芳也, 和田 哲治, 原渕 保明

    耳鼻咽喉科臨床 補冊   ( 補冊154 )   92 - 92   2019年6月

     詳細を見る

    記述言語:日本語   出版者・発行元:耳鼻咽喉科臨床学会  

    researchmap

  • 旭川医科大学における過去10年間の舌癌を除く口腔癌症例の検討

    熊井 琢美, 河野 通久, 保立 裕史, 岸部 幹, 高原 幹, 片田 彰博, 林 達哉, 原渕 保明

    耳鼻咽喉科展望   62 ( 補冊1 )   34 - 35   2019年6月

     詳細を見る

    記述言語:日本語   出版者・発行元:耳鼻咽喉科展望会  

    researchmap

  • 第4-5頸椎に石灰化を認めた石灰沈着性頸長筋腱炎の2例

    河野 通久, 後藤 孝, 坂東 伸幸, 原渕 保明

    耳鼻咽喉科臨床   112 ( 1 )   37 - 41   2019年1月

  • 入院加療を要した鼻出血症例の検討

    坂東 伸幸, 後藤 孝, 市川 晴之, 河野 通久

    日本鼻科学会会誌   57 ( 3 )   414 - 414   2018年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本鼻科学会  

    researchmap

  • 蝶形骨洞原発悪性黒色腫の一例

    河野 通久, 石田 芳也, 和田 哲治, 原渕 保明

    日本鼻科学会会誌   57 ( 3 )   539 - 539   2018年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本鼻科学会  

    researchmap

  • 頬部しびれ感を初発症状とした進行肺腺癌の1例

    市川 晴之, 坂東 伸幸, 後藤 孝, 朝日 淳仁, 原渕 翔平, 河野 通久, 原渕 保明

    日本鼻科学会会誌   57 ( 3 )   423 - 423   2018年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本鼻科学会  

    researchmap

  • 内視鏡補助下甲状腺手術(VANS)50例の検討

    坂東 伸幸, 後藤 孝, 河野 通久, 清水 一雄

    日本内分泌・甲状腺外科学会雑誌   35 ( Suppl.1 )   S148 - S148   2018年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本内分泌外科学会・日本甲状腺外科学会  

    researchmap

  • 北海道十勝地方におけるアレルギー性鼻炎症例の検討

    坂東 伸幸, 後藤 孝, 人見 会美子, 人見 知洋, 西村 洋一, 原渕 翔平, 安川 梨香, 河野 通久, 市川 晴之, 原渕 保明

    日本職業・環境アレルギー学会雑誌   25 ( 2 )   101 - 107   2018年5月

  • 当科における急性喉頭蓋炎症例の検討

    河野 通久, 後藤 孝, 坂東 伸幸, 原渕 保明

    日本気管食道科学会会報   69 ( 2 )   s40 - s40   2018年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(NPO)日本気管食道科学会  

    researchmap

  • 当科における唾液腺腫瘍症例の検討

    坂東 伸幸, 後藤 孝, 河野 通久, 市川 晴之, 高原 幹, 片田 彰博

    日本耳鼻咽喉科学会会報   121 ( 4 )   599 - 599   2018年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本耳鼻咽喉科頭頸部外科学会  

    researchmap

  • 広範囲胸壁浸潤をきたした甲状腺濾胞癌縦隔リンパ節転移

    河野 通久, 野村 研一郎, 北田 正博, 片田 彰博, 林 達哉, 原渕 保明

    日本気管食道科学会会報   69 ( 1 )   38 - 44   2018年2月

  • 北海道十勝地方におけるアレルギー性鼻炎、花粉症例の検討

    坂東 伸幸, 後藤 孝, 安川 梨香, 河野 通久, 原渕 保明

    耳鼻咽喉科免疫アレルギー   35 ( 2 )   190 - 191   2017年8月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本耳鼻咽喉科免疫アレルギー学会  

    researchmap

  • 北海道十勝地方におけるアレルギー性鼻炎、花粉症例の検討

    坂東 伸幸, 後藤 孝, 河野 通久, 原渕 保明

    日本職業・環境アレルギー学会雑誌   25 ( 1 )   81 - 81   2017年6月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本職業・環境アレルギー学会  

    researchmap

  • 甲状腺腫瘍と鑑別を要したMTX関連リンパ増殖性疾患の1例

    河野 通久, 吉崎 智貴

    耳鼻咽喉科臨床 補冊   ( 補冊146 )   128 - 128   2016年6月

     詳細を見る

    記述言語:日本語   出版者・発行元:耳鼻咽喉科臨床学会  

    researchmap

▼全件表示

講演・口頭発表等

  • 腫瘍免疫研究 in Boston

    河野通久

    日本耳鼻咽喉科免疫アレルギー感染症学会  2023年 

     詳細を見る

  • Tissue-resident memory CD8+ T cells correlate with anti-PD-1 response in head and neck cancer and expand upon cDC1 activation in tumor-draining lymph nodes to overcome PD-1 resistance

    Michihisa Kono

    American Assiciation for Cancer Research- American Head and Neck Cancer society Head and Neck Cancer Conference  2023年 

     詳細を見る

  • 鼻性NK/T 細胞リンパ腫における免疫抑制サイトカインの検討

    河野通久

    ヘルペス研究会  2021年 

     詳細を見る

  • MDM2を標的としたがんペプチドワクチン療法の基礎的解析

    河野通久

    日本耳鼻咽喉科免疫アレルギー感染症学会  2021年 

     詳細を見る

  • Interruption of MDM2 signaling augments MDM2-targeted T cell-based antitumor immunotherapy through antigen presenting machinery

    Michihisa Kono

    日本癌学会  2021年 

     詳細を見る

  • 頭頸部癌に対するMDM2-p53を標的としたがん免疫療法

    河野通久

    日本耳鼻咽喉科学会  2021年 

     詳細を見る

  • 顎下腺分泌癌の1例

    河野通久

    日本頭頸部外科学会  2019年 

     詳細を見る

  • 頭頸部癌に対するMDM2を標的としたがん免疫療法

    河野通久

    北海道医学大会腫瘍系分科会  2020年 

     詳細を見る

  • Evaluation of immune regulatory cytokines in nasal NK/T cell lymphoma

    International Symposium on Epstein-Barr Virus and associated diseases  2020年 

     詳細を見る

  • 内視鏡下に摘出した鼻腔glomangiopericytomaの1例

    河野通久

    頭頸部外科学会  2018年 

     詳細を見る

  • 石灰沈着性頸長筋腱炎の2例

    河野通久

    日耳鼻北海道地方会  2018年 

     詳細を見る

  • 蝶形骨洞原発悪性黒色腫の1例

    河野通久

    日本鼻科学会  2018年 

     詳細を見る

  • 当科における唾液腺導管癌症例の検討

    河野通久

    耳鼻咽喉科臨床学会  2019年 

     詳細を見る

  • 甲状腺濾胞癌縦隔リンパ節転移

    河野通久

    日耳鼻北海道地方会  2016年 

     詳細を見る

  • 広範囲胸骨浸潤をきたした甲状腺濾胞癌縦隔リンパ節転移

    河野通久

    気管食道科学会  2016年 

     詳細を見る

  • 当科における急性喉頭蓋炎の臨床的検討

    河野通久

    日本気管食道科学会  2017年 

     詳細を見る

  • 甲状腺腫瘍と鑑別を要したMTX関連リンパ増殖性疾患

    河野通久

    日耳鼻北海道地方会  2015年 

     詳細を見る

  • MTX関連リンパ増殖性疾患

    河野通久

    耳鼻咽喉科臨床学会  2016年 

     詳細を見る

▼全件表示

その他

  • 日本耳鼻咽喉科・頭頸部外科学会認定耳鼻咽喉科専門医

     詳細を見る

  • 緩和ケア研修会修了者

     詳細を見る

  • 医学博士

     詳細を見る

担当経験のある科目(授業)

▼全件表示

学術貢献活動

  • Biomarker Research Reviewer

    役割:査読

    2025年2月 - 現在

     詳細を見る

  • Cancer Medicien Reviewer

    役割:査読

    2025年1月

     詳細を見る

  • Cancer Investigation Reviewer

    役割:査読

    2024年11月 - 現在

     詳細を見る

  • Cell Biology and Toxicology Reviewer

    役割:査読

    2024年10月 - 現在

     詳細を見る

  • Cancer Reports Reviewer

    役割:査読

    2024年8月 - 現在

     詳細を見る

  • Heliyon Reviewer

    役割:査読

    2024年7月 - 現在

     詳細を見る

  • Expert Review of Anticancer Therapy

    役割:査読

    2024年7月 - 現在

     詳細を見る

  • Scientific Reports Reviewer

    役割:査読

    2024年6月 - 現在

     詳細を見る

  • Discovery Oncology Reviewer

    役割:査読

    2023年11月 - 現在

     詳細を見る

  • BMC Medical Genomics Reviewer

    役割:査読

    2023年5月 - 現在

     詳細を見る

  • Infectious agents and Cancer Reviewer

    役割:査読

    2023年3月 - 現在

     詳細を見る

  • Molecular and Clinical Oncology Reviewer

    役割:査読

    2023年1月 - 現在

     詳細を見る

  • Frontiers in Oncology Reviewer

    役割:査読

    2022年11月 - 現在

     詳細を見る

  • European Journal of Inflammation Reviewer

    役割:査読

    2021年11月 - 現在

     詳細を見る

  • Cancer Science Reviewer

    役割:査読

    2021年7月 - 現在

     詳細を見る

  • Nutrition and Cancer Reviewer

    役割:査読

    2021年7月 - 現在

     詳細を見る

  • Journal for Immunotherapy of Cancer Reviewer

    役割:査読

    2021年4月 - 現在

     詳細を見る

  • Cancer Immunology Immunotherapy Reviewer

    役割:査読

     詳細を見る

  • Cureus guest editor

    役割:審査・評価, 査読

     詳細を見る

  • Frontiers in Oncology editorial board

    役割:審査・評価, 査読

     詳細を見る

▼全件表示